Planned maintenance may cause outages to the Department of Health and Aged Care’s network from 5:15 pm AEDT on 30 November to 10:00 pm AEDT on 1 December 2024. Access to TGA databases such as TBS Portal, ARTG and DAEN may be affected. We apologise for any inconvenience.
ALEMBIC LACOSAMIDE, LACONAT, LACORESS, LACOSAMIDE AGH, LACOSAMIDE AGHL, LACOSAMIDE APL, LACOSAMIDE APPL, VICOMAT, VIGREN, VIMOLAC (Alembic Pharmaceuticals Australia Pty Ltd)
Product name
ALEMBIC LACOSAMIDE, LACONAT, LACORESS, LACOSAMIDE AGH, LACOSAMIDE AGHL, LACOSAMIDE APL, LACOSAMIDE APPL, VICOMAT, VIGREN, VIMOLAC
Date registered
Evaluation commenced
Decision date
Approval time
141 (255 working days)
Active ingredients
lacosamide
Registration type
New generic medicine
Indication
ALEMBIC LACOSAMIDE, LACONAT, LACORESS, LACOSAMIDE AGH, LACOSAMIDE AGHL, LACOSAMIDE APL, LACOSAMIDE APPL, VICOMAT, VIGREN, VIMOLAC (tablet) are indicated as:
- monotherapy in the treatment of partial seizures with or without secondary generalisation in patients with epilepsy aged 16 years and older.
- add-on therapy in the treatment of partial seizures with or without secondary generalisation in patients with epilepsy aged 4 years and older.